AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-8 (Canceled)

9. (Previously Presented) An antibiotic compound β-keto aliphatic acid ester isolated from *Bacillus sp.* IICT 001 and possessing the following spectral properties

UV max (MeoH): 225

¹H NMR CDCI₃(80 M $\underline{\text{H}}_2$): 0.88 t (C $\underline{\text{H}}_3$); 1.25 s, br (C $\underline{\text{H}}_2$)n; 2.16s (COC $\underline{\text{H}}_2$); 3.68 s(COOC $\underline{\text{H}}_3$) IR. ^Vmax(CHCI³): cm⁻¹ 1730 (ester), 1670 (Carbonyl).

10. (Previously Presented) A pharmaceutical composition comprising an effective amount of a β -keto aliphatic acid ester isolated from *Bacillus sp.* IICT 001 and possessing the following spectral properties

UV max (MeoH): 225

¹H NMR CDCI₃(80 M $\underline{\text{H}}_2$): 0.88 t (C $\underline{\text{H}}_3$); 1.25 s, br (C $\underline{\text{H}}_2$)n; 2.16s (COC $\underline{\text{H}}_2$); 3.68 s(COOCH₃) IR. ^Vmax(CHCI³): cm⁻¹ 1730 (ester), 1670 (Carbonyl) in admixture with a therapeutically acceptable carrier.